Cwm LLC Purchases 19,828 Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA)

CWM LLC boosted its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) by 867.4% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 22,114 shares of the company's stock after purchasing an additional 19,828 shares during the quarter. CWM LLC's holdings in Kiniksa Pharmaceuticals International were worth $491,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Braidwell LP increased its holdings in Kiniksa Pharmaceuticals International by 19.3% in the 4th quarter. Braidwell LP now owns 3,452,447 shares of the company's stock worth $68,289,000 after acquiring an additional 557,934 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Kiniksa Pharmaceuticals International by 138.9% in the 4th quarter. JPMorgan Chase & Co. now owns 477,800 shares of the company's stock worth $9,451,000 after acquiring an additional 277,827 shares during the last quarter. Millennium Management LLC increased its holdings in Kiniksa Pharmaceuticals International by 50.9% in the 4th quarter. Millennium Management LLC now owns 779,672 shares of the company's stock worth $15,422,000 after acquiring an additional 263,146 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Kiniksa Pharmaceuticals International in the 4th quarter worth about $3,955,000. Finally, Hudson Bay Capital Management LP increased its holdings in Kiniksa Pharmaceuticals International by 150.0% in the 4th quarter. Hudson Bay Capital Management LP now owns 225,000 shares of the company's stock worth $4,450,000 after acquiring an additional 135,000 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the company. Wells Fargo & Company lifted their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the stock an "overweight" rating in a report on Wednesday, July 9th. Wedbush restated an "outperform" rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a "hold" rating to a "buy" rating in a research note on Sunday, July 6th. Finally, Jefferies Financial Group raised their target price on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $39.67.

Insiders Place Their Bets

In other news, insider Ross Moat sold 27,594 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $29.02, for a total transaction of $800,777.88. Following the completion of the sale, the insider owned 9,415 shares in the company, valued at approximately $273,223.30. This trade represents a 74.56% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Barry D. Quart sold 12,336 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $30.39, for a total value of $374,891.04. Following the sale, the director owned 12,546 shares of the company's stock, valued at approximately $381,272.94. This trade represents a 49.58% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 429,504 shares of company stock worth $12,027,601. Insiders own 53.48% of the company's stock.

Kiniksa Pharmaceuticals International Stock Performance

NASDAQ KNSA traded up $0.71 during trading hours on Monday, hitting $27.04. The company had a trading volume of 669,914 shares, compared to its average volume of 560,033. Kiniksa Pharmaceuticals International, plc has a 52 week low of $17.82 and a 52 week high of $30.69. The firm has a 50 day simple moving average of $28.04 and a 200 day simple moving average of $23.80. The firm has a market capitalization of $1.97 billion, a price-to-earnings ratio of -108.16 and a beta of 0.05.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.02 by $0.09. The firm had revenue of $137.79 million during the quarter, compared to the consensus estimate of $128.35 million. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. The company's revenue for the quarter was up 72.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.25) EPS. On average, research analysts forecast that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.